Authors: Filip Málek Authors‘ workplace: Kardiovaskulární centrum, Nemocnice Na Homolce, Praha Published in: Vnitř Lék 2023; 69(E-2): 23-25 Category: doi: https://doi.org/10.36290/vnl.2023.025
Eplerenone is a selective mineralocorticoid receptor antagonist. Its approved for the therapy of patients with chronic heart failure with left ventricular systolic dysfunction and for the patients after myocardial infarction complicated by heart failure and left ventricular dysfunction. It´s also recommended for the therapy of primary hyperaldosteronism and the treatment of drug resistant hypertension.
Resistant hypertension – heart failure – eplerenone – mineralocorticoid receptors – hyperaldosteronism
1. Málek F, Špaček R. Blokáda receptoru aldosteronu v terapii chronického srdečního selhání. Cor Vasa. 2002,44 : 32-36.
2. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24 : 4-131.
3. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/ HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-e1032.
4. Pitt B, Remme W, Zannad F, et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction N Engl J Med. 2003;348 : 1309-21.
5. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364 : 11-21.
6. Mairgani G, Mále V, Málek F. The importance of a higher dose of a mineralocorticoid receptor antagonist in reducing risk of reccurent hospitalization in a patient with advanced chronic heart failure – a case report. Cor Vasa 2018;60:e527-530.
7. Capuano A, Scavone C, Vitale C, et al. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF). Int J Cardiol. 2015,200 : 15-19.
8. Widimský J, Filipovský J, Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze. Doporučení České společnosti pro hypertenzi. Hypertenze α kardiovaskulární prevence Suppl. 2022;12(2):1-25.
9. SPC Eplerenon. Available from: file:///C:/Users/11366/Downloads/eplerenon‑sandoz‑spc% 20(1).pdf.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
